| | | Firm | Analyst | | Argus Research Company | John Eade | | Bank of America Merrill Lynch | Rachel McMinn | | Barclays Capital | Jim Birchenough, MD | | BMO Capital Markets | Jason Zhang, PhD | | BWS Financial | Hamed Khorsand | | Citigroup | Yaron Werber, MD | | Cowen & Company | Phil Nadeau, PhD | | Deutsche Bank | Robyn Karnauskas | | First Global Stockbroking Ltd. | Kavita Thomas | | ISI | Mark Schoenebaum | | Jefferies & Company | Thomas Wei | | JPMorgan | Geoffrey Meacham, PhD | | Lazard Capital Markets | Joel Sendek | | Leerink Swann | Joshua Schimmer, MD | | Morgan Joseph | Shiv Kapoor | | Morningstar | Karen Andersen, CFA | | Needham | Alan Carr | | Oppenheimer | Bret Holley, PhD | | Piper Jaffray | M. Ian Somaiya | | RBC Capital Markets | Jason Kantor | | Robert W. Baird & Co | Thomas J. Russo, CFA | | Roth Capital | Edward Nash | | Sanford C. Bernstein & Co. | Geoffrey Porges, PhD | | Standard and Poors | Steven Silver | | Summer Street Research Partners | Carol Werther | | ThinkEquity | Brian Scorney | | Wedbush Pac Grow Lifesciences | Y. Katherine Xu | | William Blair & Company | John Sonnier |
|
 |
| Gilead Sciences is followed by the analysts listed above. Please note that any opinions, estimates or forecasts regarding Gilead Sciences's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Gilead Sciences or its management. Gilead Sciences does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations. |
|
